
Quick Take
Replimune Group (REPL) intends to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1/A registration statement.
The firm pioneered the first FDA-approved oncolytic immunotherapy - a neoantigen vaccine specific for patients' tumors. This is a new class of cancer treatment which uses the ability of certain viruses to selectively replicate and kill tumors.
REPL has strong collaboration opportunities, a highly experienced management team in its field and top-tier institutional investors.

